Literature DB >> 32565437

Pegloticase hypersensitivity desensitisation: an outpatient, 3-bag, 12-step protocol.

John K Botson1.   

Abstract

Pegloticase is a highly effective treatment for refractory gouty arthropathy. Unfortunately, the medication is also highly immunogenic, leading to infusion reactions, loss of drug efficacy and anaphylaxis. Desensitisation, a procedure to tolerise a patient to a medication previously causing a hypersensitivity reaction, has been used successfully in oncology for chemotherapy treatment. The same principle can be applied to other specialties. Presented is a 48-year-old man who experienced multiple, severe infusion reactions to pegloticase administered for gouty arthropathy. A rapid desensitisation was performed using an outpatient, 3-bag, 12-step protocol, which allowed multiple additional pegloticase infusions to be performed without incident. This is the first reported case of a patient successfully desensitised after an infusion reaction to pegloticase. Though additional patients are needed to confirm these results, this represents a significant opportunity to recapture and continue pegloticase therapy in patients treated for refractory gouty arthropathy. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  immunology; rheumatology

Mesh:

Substances:

Year:  2020        PMID: 32565437      PMCID: PMC7307524          DOI: 10.1136/bcr-2020-234721

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.

Authors:  Chyh-Woei Lee; Ursula A Matulonis; Mariana C Castells
Journal:  Gynecol Oncol       Date:  2004-11       Impact factor: 5.482

2.  Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Authors:  Peter E Lipsky; Leonard H Calabrese; Arthur Kavanaugh; John S Sundy; David Wright; Marsha Wolfson; Michael A Becker
Journal:  Arthritis Res Ther       Date:  2014-03-04       Impact factor: 5.156

Review 3.  Desensitization for Allergic Reactions to Chemotherapy.

Authors:  David In Chull Hong
Journal:  Yonsei Med J       Date:  2019-02       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.